| Old Articles: <Older 6491-6500 Newer> |
|---|
 |
The Motley Fool
July 27, 2010
Brian Orelli |
Better Buy: Cell Therapeutics or Sequenom? Which one deserves your dollars more?   |
The Motley Fool
July 27, 2010
Brian Orelli |
Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts. |
The Motley Fool
July 27, 2010
Brian Orelli |
Brilinta? I Think Not. AstraZeneca's new blood thinner is far from brilliant. |
The Motley Fool
July 26, 2010
Ryan McBride |
How Much Would You Pay for Genzyme? Speculation has erupted over the potential outcome of reported M&A talks between the Cambridge, MA-based biotech powerhouse Genzyme and the French drug giant Sanofi-Aventis |
The Motley Fool
July 26, 2010
Jason Moser |
A Bloody Good Stock for Investors Haemonetics' business might be a little messy, but it's the kind of company you should invest in. Haemonetics is in the business of management; blood management, that is. |
The Motley Fool
July 26, 2010
Luke Timmerman |
SonoSite's New Push: Ultrasound for an Up-Close Look at Heart Attack Risk SonoSite's new technology to help identify those at risk for a heart attack. |
The Motley Fool
July 26, 2010
Brian Orelli |
Up 20%! Guess That Hedge Wasn't Needed Onyx reports positive data for its recently acquired multiple myeloma drug. |
The Motley Fool
July 26, 2010
Brian Orelli |
Beleaguered Biotech for Sale by Owner. Maybe. Will Genzyme's management sell before the turnaround is complete? |
The Motley Fool
July 26, 2010
Tom Gardner |
A Disaster for Shareholders Two biotechnology stocks not worth the trouble. |
InternetNews
July 23, 2010 |
CSC Opens Online Medical Support Community CSC has launched an interactive, online community whose main focus is to provide a forum for health care professionals to share information on meaningful use of electronic health record technology. |
| <Older 6491-6500 Newer> Return to current articles. |
